You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19]
See all PARK7/DJ1 products (15) ...

Description

Mouse monoclonal [malphaDJ-1/E2.19] to PARK7/DJ1

Specificity

This clone has been shown to specifically recognise a fusion protein of PARK7/DJ1. It also recognises a FLAG-tagged PARK7/DJ1 expressed in eukaryotic cells. A single band is seen when Western blotting in optimised conditions with this clone. However, overloading the gel or using low dilutions can cause other bands to appear.

Tested applications

Flow Cyt, IHC-Fr, ICC/IF, WB, ICC, IHC-FoFrmore details

Cross reactivity

Reacts with

Human, Zebrafish

Does not react with

Mouse

Immunogen

Recombinant full length protein (Human).

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: PBS, pH 7.4

Concentration

Concentration information loading...

Purity

Ion Exchange Chromatography

Clonality

Monoclonal

Clone number

malphaDJ-1/E2.19

Isotype

IgM

  • - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)- PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251) image (enlarge)

  • Western blot - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)Western blot - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251) image (enlarge)

  • Immunocytochemistry/ Immunofluorescence - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)Immunocytochemistry/ Immunofluorescence - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab11251 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Protects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone.

Tissue specificity

Highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa.

Involvement in disease

Defects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).

Sequence similarities

Belongs to the peptidase C56 family.

Post-translational
modifications

Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
Cys-106 is easily oxidized to sulfinic acid.
Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress.

Cellular localization

Cytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients.

Target information above from: UniProt accessionQ99497 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • CAP1 antibody
  • DJ 1 antibody
  • DJ-1 antibody
  • DJ1 antibody
  • DJ1 protein antibody
  • DJ1 protein antibody
  • FLJ27376 antibody
  • FLJ34360 antibody
  • FLJ92274 antibody
  • Oncogene DJ1 antibody
  • OTTHUMP00000001348 antibody
  • OTTHUMP00000001349 antibody
  • OTTHUMP00000001350 antibody
  • OTTHUMP00000001351 antibody
  • Park 7 antibody
  • Park7 antibody
  • PARK7_HUMAN antibody
  • Parkinson disease (autosomal recessive early onset) 7 antibody
  • Parkinson disease (autosomal recessive, early onset) 7 antibody
  • Parkinson disease protein 7 antibody
  • Protein DJ 1 antibody
  • Protein DJ-1 antibody
  • RNA binding protein regulatory subunit antibody
  • RS antibody
  • SP22 antibody
see all

Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19] images:

  - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

- PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

Western blot using clone malphaDJ-1/E2.19 and a beta actin antibody as a loading control.

The bottom band is PARK7/DJ1, the top band is beta actin.

Lane 1: 293 cell lysate

Lane 2: MCF-7 cell lysate

Lanes 3-7: various different prostate cell lines

Lane 8: recombinant PARK7/DJ1 (that was used as immunogen for this antibody)

  Western blot - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

Western blot - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

Western blot using ab11251 at 1/500 on HeLa whole cell lysate (20µg/lane).

  Immunocytochemistry/ Immunofluorescence - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

Immunocytochemistry/ Immunofluorescence - PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

ICC/IF image of ab11251 stained human HeLa cells. The cells were PFA fixed (10 min), permabilised in TBS-T (20 min) and incubated with the antibody (ab11251, 1:500 dilution) for 1h at room temperature. 1%BSA / 10% normal goat serum / 0.3M glycine was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue).

  Flow Cytometry-Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19](ab11251)

Flow Cytometry-Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19](ab11251)

Overlay histogram showing HepG2 cells stained with ab11251 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11251, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgM [ICIGM] (ab91545, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

References for Anti-PARK7/DJ1 antibody [malphaDJ-1/E2.19] (ab11251)

This product has been referenced in:

  • Sala GLet al. The cytotoxic pathway triggered by palytoxin involves a change in the cellular pool of stress response proteins. Chem Res Toxicol 22:2009-16 (2009). WB; Human.Read more (PubMed: 19928802) »
  • Bretaud Set al. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J Neurochem 100:1626-35 (2007).Read more (PubMed: 17166173) »

See all 5 publications for this product

Publishing research using ab11251? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"